10/28/2025 16:34
Swiss Rockets Announces Strategic Exclusive License Acquisition of Cutting-Edge Sequencing Technology from MGI Tech and Complete Genomics

Swiss Rockets, MGI US LLC and Complete Genomics Inc. announced today that they entered into a exclusive license agreement with MGI Tech and Complete Genomics, USA, granting Swiss Rockets a perpetual, transferrable, sublicensable, freedom-to-operate, license for USA, Europe, Latam, Africa and Central Asia with option to expand rights into Asia-Pacific in 2026, covering patents and other intellectual property necessary for development, manufacturing, and sales of the next-generation CoolMPS seque...

11/04/2025 21:47
The Estée Lauder Companies Announces Secondary Offering of Class A Common Stock by Selling Stockholders

The Estée Lauder Companies Inc. (NYSE: EL) today announces that trusts affiliated with descendants of Leonard A. Lauder (the “Selling Stockholders”) propose to sell 11,301,323 shares of the Company’s Class A Common Stock, par value $.01 per share, through a proposed registered public offering (the “Offering”). The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Class A Common Stock in the Offering and will not receive any procee...

12/08/2025 13:00
From Pilots to Profit: NTT DATA's 2026 Global AI Report Shows How Top Performers Turn AI Vision Into Value

NTT DATA, a global leader in AI, digital business and IT services, today released the 2026 Global AI Report: A playbook for AI leaders. The playbook is based on the company’s new benchmark research and reveals how “AI leaders” are separating from competitors through strategy and execution. The analysis is based on a survey of 2,567 senior executives across 35 countries and 15 industries. Only 15% of participating organizations qualified as “AI leaders,” defined by clear AI strategies, mature o...

12/08/2025 13:00
AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced it has received the first delivery of high-activity 228Th, the parent isotope of 212Pb and a key starting material to produce the alpha-emitter 212Pb, used to manufacture ADVC001, the company’s lead asset, and other 212Pb-based radioligand therapies in the pipeline. This delivery marks a major milestone for the company and underscores the industry leading infrastru...

12/08/2025 13:00
Pink Changing Lives®: Mary Kay Builds 11th Preschool in Sri Lanka, Turning a Dream Into Thousands of New Beginnings

Mary Kay Inc., a global champion for women’s empowerment, is turning pink into purpose through its Pink Changing Lives® Program to raise awareness and funds to support life-changing programs advancing cancer research, support survivors of domestic violence, protect our planet’s most precious resources, and create opportunities that help women and their families thrive. Since 1996, the multi-faceted Pink Changing Lives® Program has donated over $230 million in monetary and in-kind donations to i...

12/08/2025 13:00
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data reinforce BRUKINSA® (zanubrutinib) as the foundational Bruton’s tyrosine kinase inhibitor (BTKi) of choice. “At ASH 2025, we will present new data f...

11/04/2025 22:12
IFF Reports Third Quarter 2025 Results

IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Consolidated Summary: Management Commentary “Our third quarter results demonstrate continued execution in a tough operating environment,” said Erik Fyrwald, CEO of IFF. “Sales momentum in Scent and Taste remain solid, supported by strong new win contributions. This performance helped offset short-term pressures in Health and Biosciences - which we are addressing by strengthening our ...

11/04/2025 22:07
SymphonyAI Launches Sensa Risk Intelligence to Modernize Financial Compliance With Proven AI Expertise

SymphonyAI, a global leader in Vertical AI product platforms, today announced the launch of Sensa Risk Intelligence (SRI), an AI-native platform built on decades of regulatory and financial crime expertise. Designed for trusted deployment in critical financial environments, SRI helps institutions reduce compliance costs, improve detection accuracy, and modernize their operations with confidence. As regulations evolve and alert volumes surge, compliance teams face growing operational strain. S...